Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Analysis

Editor-in-Chief

ISSN (Print): 1573-4129
ISSN (Online): 1875-676X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

A Highly Sensitive LC–MS/MS Method Development and Validation of Fedratinib in Human Plasma and Pharmacokinetic Evaluation in Healthy Rabbits

Author(s): Ayesha Begum Khadernaick*, Gubbiyappa Shiva Kumar, Pamu Sandhya and Darna Bhikshapathi

Volume 17, Issue 6, 2021

Published on: 12 May, 2020

Page: [782 - 791] Pages: 10

DOI: 10.2174/1573412916999200512121023

Price: $65

conference banner
Abstract

Background: A simple and sensitive quantitation analytical technique by liquid chromatography– tandem mass spectrometry (LC-MS/MS) is essential for fedratinib in biological media with kinetic study in healthy rabbits.

Objective: The main objectives of the present research work are the development of the LC-MS/MS method and to validate a procedure for the quantitation of fedratinib and its application to kinetic study in rabbits.

Methods: Separation of processed samples was done on zorbax SB C18 column (50mm×4.6 mm) 3.5μm with a movable phase of methanol, acetonitrile and 0.1% formic acid in the ratio of 30:60:10. The movable phase was monitored through column at 0.8 ml/min flow rate. The drug and ibrutinib internal standard (IS) were evaluated by monitoring the transitions of m/z -525.260/57.07 and 441.2/55.01 for fedratinib and IS, respectively in multiple reaction monitoring mode.

Results: The linear equation and coefficient of correlation (R2) results were y =0.00348x+0.00245 and 0.9984, respectively. Intra and inter-day precision RSD findings of the developed technique were found in the range of 2.4 - 5.3% for the quality control (QC)-samples (252.56, 1804.0 and 2706 ng/ml). The proposed method was subjected to pharmacokinetic study in healthy rabbits and the kinetic study, fedratinib showed mean AUClast 13190±18.1 hr*ng/ml and Cmax was found to be 3550±4.31 ng/ml in healthy rabbits.

Conclusion: The validated method can be applicable for the pharmacokinetic and toxicokinetic studies in the clinical and forensic analysis of fedratinib in different kinds of biological matrices successfully.

Keywords: Fedratinib, myelofibrosis, pharmacokinetics, LC-MS/MS, accuracy, phosphorylation.

« Previous Next »
Graphical Abstract

[1]
Pardanani, A.; Harrison, C.; Cortes, J.E.; Cervantes, F.; Mesa, R.A.; Milligan, D.; Masszi, T.; Mishchenko, E.; Jourdan, E.; Vannucchi, A.M.; Drummond, M.W.; Jurgutis, M.; Kuliczkowski, K.; Gheorghita, E.; Passamonti, F.; Neumann, F.; Patki, A.; Gao, G.; Tefferi, A. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial. JAMA Oncol., 2015, 1(5), 643-651.
[http://dx.doi.org/10.1001/jamaoncol.2015.1590] [PMID: 26181658]
[2]
Jamieson, C.; Hasserjian, R.; Gotlib, J.; Cortes, J.; Stone, R.; Talpaz, M.; Thiele, J.; Rodig, S.; Pozdnyakova, O. Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis. J. Transl. Med., 2015, 13, 294.
[http://dx.doi.org/10.1186/s12967-015-0644-4] [PMID: 26357842]
[3]
Zhang, M.; Xu, C.; Ma, L.; Shamiyeh, E.; Yin, J.; von Moltke, L.L.; Smith, W.B. Effect of food on the bioavailability and tolerability of the JAK2-selective inhibitor fedratinib (SAR302503): Results from two phase I studies in healthy volunteers. Clin. Pharmacol. Drug Dev., 2015, 4(4), 315-321.
[http://dx.doi.org/10.1002/cpdd.161] [PMID: 27136912]
[4]
Zhang, M.; Xu, C.R.; Shamiyeh, E.; Liu, F.; Yin, J.Y.; von Moltke, L.L.; Smith, W.B. A randomized, placebo-controlled study of the pharmacokinetics, pharmacodynamics, and tolerability of the oral JAK2 inhibitor fedratinib (SAR302503) in healthy volunteers. J. Clin. Pharmacol., 2014, 54(4), 415-421.
[http://dx.doi.org/10.1002/jcph.218] [PMID: 24165976]
[5]
Pardanani, A.; Gotlib, J.R.; Jamieson, C.; Cortes, J.E.; Talpaz, M.; Stone, R.M.; Silverman, M.H.; Gilliland, D.G.; Shorr, J.; Tefferi, A. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J. Clin. Oncol., 2011, 29(7), 789-796.
[http://dx.doi.org/10.1200/JCO.2010.32.8021] [PMID: 21220608]
[6]
Roskoski, R. Jr Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. Pharmacol. Res., 2016, 111, 784-803.
[http://dx.doi.org/10.1016/j.phrs.2016.07.038] [PMID: 27473820]
[7]
Pardanani, A.; Hood, J.; Lasho, T.; Levine, R.L.; Martin, M.B.; Noronha, G.; Finke, C.; Mak, C.C.; Mesa, R.; Zhu, H.; Soll, R.; Gilliland, D.G.; Tefferi, A. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia, 2007, 21(8), 1658-1668.
[http://dx.doi.org/10.1038/sj.leu.2404750] [PMID: 17541402]
[8]
FDA approves treatment for patients with rare bone marrow disorder. FDA., 2019 16August; Retrieved 16 August. 2019.
[9]
Celgene to Acquire Impact Biomedicines, Adding Fedratinib to Its Pipeline of Novel Therapies for Hematologic Malignancies (NASDAQ: CELG) Ir.celgene.com., 2015. Retrieved 2018-01-18..
[10]
Kumar, S. Moola, BalaSekhara Reddy Challa.; Chandrasekhar, KothapalliBannoth. Quantification of tolvaptan in rabbit plasma by LC–MS/MS: Application to a pharmacokinetic study. J. Pharm. Anal., 2015, 5, 371-377.
[http://dx.doi.org/10.1016/j.jpha.2014.09.001]
[11]
Tejas, D. Komal, Chaudhary.; Priti, Mehta. Development of LC-MS/MS method for determination of iloperidone in rabbit plasma: application to a pharmacokinetic study. Int. J. Pharm. Pharm. Sci., 2013, 7, 294-297.
[12]
Kumar Moola, S. BalaSekhara Reddy, Challa; Chandrasekhar, K. B. Bioanalytical method development and validation of eszopiclone in rabbit plasma by HPLC-MS/MS and its application to pharmacokinetic study. International Journal of Biological & Pharmaceutical Research, 2014, 5, 719-727.
[13]
Neelima, P. Chandanam, Sreedhar.; SreenivasRao, T.; Veera Reddy, S. Development and validation of liquid chromatography- tandem mass pectrometry for determination of olanzapine in rabbit plasma. Int. J. Pharma Sci., 2014, 5, 151-159.
[14]
Chandrasekar, M.J.N.; Chandrasekar, A.J.; Krishnaraj, K.; Muralidharan, S.; Rajan, S.; Suresh, B. Liquid Chromatography-Mass Spectrometry Determination of Cetrizine Hydrochloride in Rabbit Plasma. Asian J. Chem., 2009, 21, 5821-5828.
[15]
FDA Guidance for Industry, Bioanalytical Method Validation, US Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM), 2001 May,
[16]
European Medicines Agency. Guideline on bioanalytical method validation, 2011.
[17]
ICH Q2B.. Harmonized Tripartite Guideline, Validation of Analytical Procedure: Methodology, IFPMA Proceedings of the International Conference on Harmonization, Geneva1996..
[18]
del Mar Ramírez Fernández, M.; Wille, S.M.R.; Samyn, N. Quantitative method validation for the analysis of 27 antidepressants and metabolites in plasma with ultraperformance liquid chromatography-tandem mass spectrometry. Ther. Drug Monit., 2012, 34(1), 11-24.
[http://dx.doi.org/10.1097/FTD.0b013e31823bf0fd] [PMID: 22210095]
[19]
Woźniakiewicz, M.; Wietecha-Posłuszny, R.; Moos, A.; Wieczorek, M.; Knihnicki, P.; Kościelniak, P. Development of microextraction by packed sorbent for toxicological analysis of tricyclic antidepressant drugs in human oral fluid. J. Chromatogr. A, 2014, 1337, 9-16.
[http://dx.doi.org/10.1016/j.chroma.2014.02.037] [PMID: 24636563]
[20]
Chambers, E.E.; Woodcock, M.J.; Wheaton, J.P.; Pekol, T.M.; Diehl, D.M. Systematic development of an UPLC-MS/MS method for the determination of tricyclic antidepressants in human urine. J. Pharm. Biomed. Anal., 2014, 88, 660-665.
[http://dx.doi.org/10.1016/j.jpba.2013.09.001] [PMID: 24239905]
[21]
Patel, D.S.; Sharma, N.; Patel, M.C.; Patel, B.N.; Shrivastav, P.S.; Sanyal, M. Development and validation of a selective and sensitive LC-MS/MS method for determination of cycloserine in human plasma: application to bioequivalence study. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2011, 879(23), 2265-2273.
[http://dx.doi.org/10.1016/j.jchromb.2011.06.011] [PMID: 21727043]
[22]
Yadav, M.; Shrivastav, P.S. Incurred sample reanalysis (ISR): a decisive tool in bioanalytical research. Bioanalysis, 2011, 3(9), 1007-1024.
[http://dx.doi.org/10.4155/bio.11.76] [PMID: 21545349]
[23]
Hewavitharana, A.K. Matrix matching in liquid chromatography-mass spectrometry with stable isotope labelled internal standards--is it necessary? J. Chromatogr. A, 2011, 1218(2), 359-361.
[http://dx.doi.org/10.1016/j.chroma.2010.11.047] [PMID: 21159347]
[24]
Bonfiglio, R.; King, R.C.; Olah, T.V.; Merkle, K. The effects of sample preparation methods on the variability of the electrospray ionization response for model drug compounds. Rapid Commun. Mass Spectrom., 1999, 13(12), 1175-1185.
[http://dx.doi.org/10.1002/(SICI)1097-0231(19990630)13:12<1175:AID-RCM639>3.0.CO;2-0] [PMID: 10407294]
[25]
Cheng, Y.; Lu, Z.; Neue, U. Ultrafast liquid chromatography/ultraviolet and liquid chromatography/tandem mass spectrometric analysis. Rapid Commun. Mass Spectrom., 2001, 15(2), 141-151.
[http://dx.doi.org/10.1002/1097-0231(20010130)15:2<141:AID-RCM201>3.0.CO;2-I] [PMID: 11180543]
[26]
Hayward, M.J.; Munson, J.L.; Conneely, G.; Hargiss, L.O. What Limits Productivity in High Flow Fast LC/MS? Proceedings of the 49th ASMS Conference on Mass Spectrometry and Allied Topics, 2001.Chicago, IL
[27]
Buhrman, D.L.; Price, P.I.; Rudewiczcor, P.J. Quantitation of SR 27417 in human plasma using electrospray liquid chromatography-tandem mass spectrometry: A study of ion suppression. J. Am. Soc. Mass Spectrom., 1996, 7(11), 1099-1105.
[http://dx.doi.org/10.1016/S1044-0305(96)00072-4] [PMID: 24203071]
[28]
Jemal, M.; Ouyang, Z. The need for chromatographic and mass resolution in liquid chromatography/tandem mass spectrometric methods used for quantitation of lactones and corresponding hydroxy acids in biological samples. Rapid Commun. Mass Spectrom., 2000, 14(19), 1757-1765.
[http://dx.doi.org/10.1002/1097-0231(20001015)14:19<1757:AID-RCM90>3.0.CO;2-C] [PMID: 11006583]
[29]
FDA Guidance for Industry.Center for Drug Evaluation and Research. Biopharmaceutics, BioanalyticalMethod Validation., 2001.. http://www.fda.gov/cder/guidance/index.htm Issued 5/2001.
[30]
Schultz, G.A.; Corso, T.N.; Prosser, S.J.; Zhang, S. A fully integrated monolithic microchip electrospray device for mass spectrometry. Anal. Chem., 2000, 72(17), 4058-4063.
[http://dx.doi.org/10.1021/ac000325y] [PMID: 10994965]
[31]
Temesi, D.; Law, B. The Effect of LC Eluent Composition on MS Responses Using Electrospray Ionization. LC GC, 1999, 17, 626-632.
[32]
King, R.; Bonfiglio, R.; Fernandez-Metzler, C. Miller- Stein, C.; Olah, T. Mechanistic Investigationof Ionization Suppression in Electrospray Ionization. J. Am. Soc. Mass Spectrom., 2000, 11, 942-950.
[http://dx.doi.org/10.1016/S1044-0305(00)00163-X] [PMID: 11073257]
[33]
Doerge, D.R.; Fogle, C.M.; Paule, M.G.; McCullagh, M.; Bajic, S. Analysis of Methylphenidate and its Metabolite RitalinicAcid in Monkey Plasma by Liquid Chromatography/Electrospray Ionization Mass Spectrometry. Rapid Commun. Mass Spectrom., 2000, 14, 610-623.
[http://dx.doi.org/10.1002/(SICI)1097-0231(20000430)14:8<619:AID-RCM916>3.0.CO;2-2]
[34]
Murphy, A.T.; Kasper, S.C.; Gillespie, T.A.; Delong, A.F. Determination of xanomeline and active metabolite, N-desmethylxanomeline, in human plasma by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry. J. Chromatogr. B Biomed. Appl., 1995, 668(2), 273-280.
[http://dx.doi.org/10.1016/0378-4347(95)00080-3] [PMID: 7581862]
[35]
Tiller, P.R.; Cunniff, J.; Land, A.P.; Schwartz, J.; Jardine, I.; Wakefield, M.; Lopez, L.; Newton, J.F.; Burton, R.D.; Folk, B.M.; Buhrman, D.L.; Price, P.; Wu, D. Drug quantitation on a benchtop liquid chromatography-tandem mass spectrometry system. J. Chromatogr. A, 1997, 771(1-2), 119-125.
[http://dx.doi.org/10.1016/S0021-9673(97)00147-7] [PMID: 9210315]
[36]
Schweingruber, H.; Dunyach, J.J.; Olney, T.N.; Taylor, D.; Churchill, M.; Amad, M.; Winnik, W.; Paul, G.; Schoen, A.E.; Campbell, C. Advantages and Limitations of Increased Mass Resolution for Quantitative SRM Analysis on a Triple Stage QuadrupoleMass Spectrometer. Proceedings of the 49th ASMS Conference on Mass Spectrometry and Allied Topics, 2001.Chicago,IL
[37]
Henion, J.; Brewer, E.; Rule, G. Sample Preparation for LC/MS/MS: Knowing the Basic Requirements andthe Big Picture of an LC/MS System can Ensure Success in Most Instances. Anal. Chem., 1998, 70, 650A-656A.
[http://dx.doi.org/10.1021/ac981991q] [PMID: 9784742]
[38]
Simpson, H.; Berthemy, A.; Buhrman, D.; Burton, R.; Newton, J.; Kealy, M.; Wells, D.; Wu, D. High throughput liquid chromatography/mass spectrometry bioanalysis using 96-well disk solid phase extraction plate for the sample preparation. Rapid Commun. Mass Spectrom., 1998, 12(2), 75-82.
[http://dx.doi.org/10.1002/(SICI)1097-0231(19980131)12:2<75:AID-RCM112>3.0.CO;2-C] [PMID: 9470219]
[39]
Watt, A.P.; Morrison, D.; Locker, K.L.; Evans, D.C. Higher throughput bioanalysis by automation of a protein precipitation assay using a 96-well format with detection by LC-MS/MS. Anal. Chem., 2000, 72(5), 979-984.
[http://dx.doi.org/10.1021/ac9906633] [PMID: 10739201]
[40]
Allanson, J.P.; Biddlecombe, R.A.; Jones, A.E. Pleasance, The Use of Automated Solid-Phase Extraction in the 96-Well Format for High Throughput BioanalysisUsing Liquid Chromtography Coupled to Tandem Mass Spectrometry. Rapid Commun. Mass Spectrom., 1996, 10, 811-816.
[http://dx.doi.org/10.1002/(SICI)1097-0231(199605)10:7<811:AID-RCM561>3.0.CO;2-Q]
[41]
Janiszewski, J.; Schneider, P.; Hoffmaster, K.; Swyden, M.; Wells, D.; Fouda, H. Automated sample preparation using membrane microtiter extraction for bioanalytical mass spectrometry. Rapid Commun. Mass Spectrom., 1997, 11(9), 1033-1037.
[http://dx.doi.org/10.1002/(SICI)1097-0231(19970615)11:9<1033:AID-RCM951>3.0.CO;2-5] [PMID: 9204578]
[42]
Jemal, M.; Teitz, D.; Ouyang, Z.; Khan, S. Comparison of Plasma Sample Purification by Manual Liquid-Liquid Extraction Automated 96-Well.,.
[43]
Jemal, M.; Teitz, D.; Ouyang, Z.; Khan, S. Comparison of plasma sample purification by manual liquid-liquid extraction, automated 96-well liquid-liquid extraction and automated 96-well solid-phase with tandem mass spectrometry. J. Chromatogr. B Biomed. Sci. Appl., 1999, 732(2), 501-508.
[http://dx.doi.org/10.1016/S0378-4347(99)00323-0] [PMID: 10517373]
[44]
Zhang, N.; Hoffman, K.L.; Li, W.; Rossi, D.T. Semi-automated 96-well liquid-liquid extraction for quantitation of drugs in biological fluids. J. Pharm. Biomed. Anal., 2000, 22(1), 131-138.
[http://dx.doi.org/10.1016/S0731-7085(99)00247-2] [PMID: 10727132]
[45]
Murphy, A.T.; Johnson, J.T.; Ackermann, B.L.; Gillespie, T.A.; Garner, C.O. Bioavailability of Zyprexa Lead Generation Formulations in Dog Plasma Using LC/MS/MS Detection of Protein Precipitation Supernatants Injected From 96-Well MicrotiterPlates. Proceedings of the 46th ASMS Conference on Mass Spectrometry and Allied Topics, 1998.Orlando,FL
[46]
Sanson, A.L.; Silva, S.C.R.; Martins, M.C.G.; Giusti-Paiva, A.; Maia, P.P.; Martins, I. Liquid-liquid extraction combined with high performance liquid chromatography-diode arrayultra-violet for simultaneous determination of antineoplastic drugs inplasma. Braz. J. Pharm. Sci., 2011, 47, 363-371.
[http://dx.doi.org/10.1590/S1984-82502011000200017]
[47]
Ahmad, S.; Kalra, H.; Gupta, A.; Raut, B.; Hussain, A.; Rahman, M.A. HybridSPE: A novel technique to reduce phospholipid-based matrix effect in LC-ESI-MS Bioanalysis. J. Pharm. Bioallied Sci., 2012, 4(4), 267-275.
[http://dx.doi.org/10.4103/0975-7406.168023] [PMID: 23248558]
[48]
Zhou, J.; Gao, S.; Zhang, F.; Jiang, B.; Zhan, Q.; Cai, F.; Li, J.; Chen, W. Liquid chromatography-tandem mass spectrometry method for simultaneous determination of seven commonly used anticancer drugs in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2012, 906, 1-8.
[http://dx.doi.org/10.1016/j.jchromb.2012.07.033] [PMID: 22959676]
[49]
Liu, G.; Aubry, A.F. Best Practices.Biological Sample Preparation For LC-MS Bioanalysis. In: Handbook of LC-MS Bioanalysis; Li, W.; Zhang, J., Eds.; John Wiley & Sons, Inc. : Hoboken, New Jersey, 2013, pp. 165-184.
[50]
Jessome, L.L.; Volmer, D.A. Ion Suppression: A Major Concern for Mass Spectrometry. LC GC N. Am., 2006, 24, 498-510.
[51]
Buszewski, B.; Noga, S. Hydrophilic interaction liquid chromatography (HILIC)--a powerful separation technique. Anal. Bioanal. Chem., 2012, 402(1), 231-247.
[http://dx.doi.org/10.1007/s00216-011-5308-5] [PMID: 21879300]
[52]
Bowers, L.D. Analytical goals in therapeutic drug monitoring. Clin. Chem., 1998, 44(2), 375-380.
[http://dx.doi.org/10.1093/clinchem/44.2.375] [PMID: 9474048]
[53]
U.S. Department of Health and Human Services Food and Drug Administration. Guidance for Industry; Bioanalytical Method Validation, 2001, pp. 1-22.

Rights & Permissions Print Cite
Article Metrics
16
1
© 2024 Bentham Science Publishers | Privacy Policy